Erratum: Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Publication
, Journal Article
Published in: JCO Precision Oncology
April 2024
Duke Scholars
Published In
JCO Precision Oncology
DOI
EISSN
2473-4284
Publication Date
April 2024
Issue
8
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Erratum: Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. (2024). JCO Precision Oncology, (8). https://doi.org/10.1200/po.24.00121
“Erratum: Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.” JCO Precision Oncology, no. 8 (April 2024). https://doi.org/10.1200/po.24.00121.
Erratum: Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precision Oncology. 2024 Apr;(8).
“Erratum: Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.” JCO Precision Oncology, no. 8, American Society of Clinical Oncology (ASCO), Apr. 2024. Crossref, doi:10.1200/po.24.00121.
Erratum: Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precision Oncology. American Society of Clinical Oncology (ASCO); 2024 Apr;(8).
Published In
JCO Precision Oncology
DOI
EISSN
2473-4284
Publication Date
April 2024
Issue
8
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- 3211 Oncology and carcinogenesis